A major passive holder has shed roughly 85% of its position in 32 days, now just above the 5% reporting threshold. Monitor for further sales that could bring the stake below 5%, which would remove a large overhang but also signal continued lack of conviction.
PYXS drugs
PYXS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $1.64entry
- T+1 · 13d ago +1.22%α −0.43% · $1.66
- T+5 · 7d ago −0.61%α −0.02% · $1.63
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Laurion Capital Management LP filed an amended Schedule 13G disclosing a reduced passive stake of 4,300,888 shares (5.16%) in Pyxis Oncology as of September 30, 2026, down from 27,988,714 shares (17.5%) reported just 32 days earlier. This represents a substantial reduction in a previously large passive position.
Key Financial Metrics
Key Facts
- Laurion Capital Management LP disclosed beneficial ownership of 4,300,888 shares of Pyxis Oncology common stock, representing 5.16% of shares outstanding as of September 30, 2026.
- This is a significant reduction from the 27,988,714 shares (17.5%) reported in the prior SC 13G/A filed on October 2, 2026.
- The filing is made under Rule 13d-1(b), confirming a passive investment intent with no control purpose.
- The stake is held through Laurion Capital Master Fund Ltd. and other funds managed by Laurion Capital.
Financial Impact
Laurion Capital reduced its stake from approximately 27.99 million shares to 4.30 million shares, a reduction of roughly 23.69 million shares (about 84.6% of the prior position). Based on the current market cap of $226M, the sold stake was worth approximately $122M at the time of sale.
Risk Factors
- Laurion Capital may continue to reduce its position, potentially selling below the 5% threshold and ceasing to file 13G amendments.
- The rapid reduction by a sophisticated hedge fund could indicate negative non-public information or deteriorating fundamentals.
- The remaining 5.16% stake still represents a meaningful overhang if the fund continues to exit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001390202-26-000019 |
| Document: 0001390202-26-000019-index.html | 0001390202-26-000019 |
| Document: 0001390202-26-000019.txt | 0001390202-26-000019 |
Track record
25 reports on PYXS
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Viewing Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers